SC Filed 2020-04-16 Event — SEC 0001072613-20-000163 →

New Enterprise Associates 16, L.P. → Trevi Therapeutics, Inc. TRVI

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

10 filings by this filer

9 other filings in the data moat

Short Interest · settle 2026-07-15

DTC 4.76

12,653,483 shares short · -8.8% vs prior

Institutional Consensus · 2026-03-31

Held by elite portfolio managers

2 holders · $50.68M

Point72 Asset MgmtViking Global

Other 13D/G Filings on Trevi Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2025-08-11	SCHEDULE	New Enterprise Associates 16, L.P.	12.00%	15,074,080	view →

Other Filings by New Enterprise Associates 16, L.P.

Filed	Form	Issuer	Stake	Shares
2025-08-18	SCHEDULE	Marker Therapeutics, Inc. MRKR	12.60%	1,625,678	view →
2025-08-11	SCHEDULE	Trevi Therapeutics, Inc. TRVI	12.00%	15,074,080	view →
2022-01-05	SC	Metacrine, Inc.	—	—	view →
2021-04-14	SC	GENOCEA BIOSCIENCES, INC.	—	—	view →
2021-03-26	SC	Marker Therapeutics, Inc. MRKR	—	—	view →
2021-03-11	SC	Allakos Inc.	—	—	view →
2020-08-03	SC	GENOCEA BIOSCIENCES, INC.	—	—	view →
2019-05-28	SC	X4 Pharmaceuticals, Inc XFOR	—	—	view →
2019-02-22	SC	GENOCEA BIOSCIENCES, INC.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →